興科蓉醫藥(06833.HK)上半年收益增長33.4%至11.3億元
格隆匯9月1日丨興科蓉醫藥(06833.HK)發佈公吿，截至2022年6月30日止六個月，報吿期內，集團收益增長33.4%至人民幣11.3億元，其中人血白蛋白注射液銷售收益增長約人民幣3.22億元，醫美服務收入增加人民幣250萬元。隨着集團收益增加，報吿期內，集團毛利增加人民幣3470萬元至人民幣1.92億元，實現純利約人民幣6190萬元，公司擁有人應占純利為人民幣6190萬元，每股基本盈利為人民幣0.03049元。
報吿期內，集團人血白蛋白注射液銷售額為人民幣11.27億元，相比2021年同期增加約人民幣3.22億元，增幅40%，而醫美服務收入約為人民幣250萬元。報吿期內實現毛利共計人民幣1.92億元，相較2021年同期毛利人民幣1.575億元同比增加人民幣3470萬元，增幅22%，毛利的增加主要是由於報吿期內集團自營人血白蛋白銷售增加所致。
在疫情的持續影響下，整個進口人血白蛋白的供應都面臨着各方面的挑戰。不同於其他醫藥產品供應，血液製品的進口環節更復雜，進口週期更長。隨着疫情的控制和進口工作恢復正常，預計2022年下半年的批簽發量會出現明顯的反彈並且全年有可能超越去年的供應量。集團將持續擴大行銷推廣網路，加強對行銷團隊的管控，完善激勵制度，不斷推進網路管道下沉。同時通過開發與醫院、藥房的多模式合作方式向終端市場延伸，為集團提升利潤貢獻，打造核心行銷能力和建立優質的終端推廣網路。
隨着集團在去年正式啟動醫美行業的產業佈局，集團醫美產品線的首款產品“少女針”的研發工作也在今年得以順利地開展。目前該專案已經完成了實驗室階段的開發工作，預計將在今年下半年開展中試生產。集團將持續投入所需的人力和資源以期推動該產品的早日上市。同時，集團也在持續調研醫美市場並將依託聚己內酯原材料開發系列產品“PCL+X”，衍生出多種醫美產品。此外，集團將繼續加強企業內部控制體系建設，強化風險管理，亦高度關注企業社會責任，並在集團管治中踐行。集團將為員工提供理想的職業發展平台，為股東創造價值而不懈努力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
